J&J signs on Xencor for a $100M licensing deal targeting CD20, looking to press its advantage in bispecifics

With a recent approval for lung cancer bispecific amivantamab, J&J is looking to build a franchise in that space with a growing crop of drugs …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J signs on Xen­cor for a $100M li­cens­ing deal tar­get­ing CD20, look­ing to press its ad­van­tage in bis­pecifics